Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Appili Therapeutics Inc (APLI.TO)

Appili Therapeutics Inc (APLI.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 4,851
  • Shares Outstanding, K 121,266
  • Annual Sales, $ 334 K
  • Annual Income, $ -9,243 K
  • 60-Month Beta 0.62
  • Price/Sales 3.69
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade APLI.TO with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm -0.04
  • Most Recent Earnings $0.00 on N/A
  • Latest Earnings Date 02/13/24
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/24
See More
  • Average Estimate -0.01
  • Number of Estimates 1
  • High Estimate -0.01
  • Low Estimate -0.01
  • Prior Year -0.02
  • Growth Rate Est. (year over year) +50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.0250 +40.00%
on 03/27/24
0.0600 -41.67%
on 04/02/24
unch (unch)
since 03/14/24
3-Month
0.0250 +40.00%
on 03/27/24
0.0600 -41.67%
on 04/02/24
+0.0050 (+16.67%)
since 01/17/24
52-Week
0.0250 +40.00%
on 03/27/24
0.0800 -56.25%
on 09/25/23
unch (unch)
since 04/13/23

Most Recent Stories

More News
Stocks in play: Appili Therapeutics Inc.

Has entered into a definitive agreement with respect to an unsecured $300,000 bridge loan from Bloom ...

APLI.TO : 0.0350 (-12.50%)
Stocks in play: Appili Therapeutics Inc.

Announced its financial and operational results for the fiscal year ended March 31, 2023. The net loss ...

APLI.TO : 0.0350 (-12.50%)
Appili Therapeutics Appoints Dr. Gary Nabors as Chief Development Officer

Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that...

APLI.TO : 0.0350 (-12.50%)
APLIF : 0.0292 (+0.69%)
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2023

Appili Therapeutics Inc. (TSX: APLI, OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its...

APLI.TO : 0.0350 (-12.50%)
APLIF : 0.0292 (+0.69%)
Appili Therapeutics Appoints Dr. Carl Gelhaus and Arthur Baran to support the ATI-1701 Biodefense Vaccine Program

Appili Therapeutics Inc. (TSX: APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, has named Carl Gelhaus,...

APLI.TO : 0.0350 (-12.50%)
APLIF : 0.0292 (+0.69%)
Stocks in play: Appili Therapeutics Inc.

Announced that the United States Patent and Trademark Office (“USPTO”) has issued a Notice of Allowance ...

APLI.TO : 0.0350 (-12.50%)
Appili Therapeutics Announces Notice of Allowance from the U.S. Patent and Trademark Office for ATI-1501 Liquid Oral Reformulation of Metronidazole

Appili Therapeutics Inc. (TSX:APLI; OTCQB: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense products, today announced...

APLI.TO : 0.0350 (-12.50%)
APLIF : 0.0292 (+0.69%)
Appili Therapeutics ATI-1701 Biodefense Vaccine Secures ~US$14 Million of Funding from the U.S. Department of Defense in Partnership with the U.S. Air Force Academy

Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced that...

APLI.TO : 0.0350 (-12.50%)
APLIF : 0.0292 (+0.69%)
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2023

Appili Therapeutics Inc. (TSX:APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced its...

APLI.TO : 0.0350 (-12.50%)
APLIF : 0.0292 (+0.69%)
Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders

Appili Therapeutics Inc. (TSX: APLI; OTCQX: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and biodefense, today announced the...

APLI.TO : 0.0350 (-12.50%)
APLIF : 0.0292 (+0.69%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Key Turning Points

3rd Resistance Point 0.0350
2nd Resistance Point 0.0350
1st Resistance Point 0.0350
Last Price 0.0350
1st Support Level 0.0350
2nd Support Level 0.0350
3rd Support Level 0.0350

See More

52-Week High 0.0800
Fibonacci 61.8% 0.0590
Fibonacci 50% 0.0525
Fibonacci 38.2% 0.0460
Last Price 0.0350
52-Week Low 0.0250

See More

Business Summary

Appili Therapeutics Inc is a biopharmaceutical company. The company is engaged in novel antibiotic and anti-infective therapies to help patients suffering from serious infections. Its anti-infective portfolio currently includes major programs namely ATI-2307, ATI-1701, ATI-1503, ATI-1501 and Favipiravir....

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar